Navigation Links
Mayuka Labs R&D Centre Gets DSIR Recognition
Date:1/12/2009

NEW DELHI, India, January 12 /PRNewswire/ -- New Delhi based Mayuka Labs Private Limited has received recognition for its in-house research & development facility from the department of scientific and industrial research (DSIR) under the ministry of science and technology, Government of India.

With twenty-one scientists working round the clock at its R&D and Pilot unit at Nacharam, Mayuka Labs has crossed this milestone in its first year of operations. The company has filed two international PCT patents in 2008 and is working on new process technologies on 12 different molecules. The companies customer base ranges from big pharma clients like Boehringer Ingelheim to leading generic companies like Mylan subsidiary Matrix Labs, Dr. Reddy's and Unimark Remedies.

"We create value for our customers through innovative new processes. As Thomas Friedman put it, this is a flat and deeply interconnected world and our R&D teams work 24/7 to cater to customers across the world. The DSIR recognition for our R&D, is a key milestone as we continue to drive efficiencies in the Custom Research, Custom Synthesis and Custom Manufacturing space," said Dr.Chandra Sekhar N K, Chairman and Managing Director, Mayuka Labs.

With this accreditation, Mayuka Labs is entitled to receive support from government establishments such as Council of Scientific & Industrial Research (CSIR), Department of Biotechnology (DBT) and the Department of Science and Technology (DST) for its projects.

According to the DSIR website there are only one thousand two hundred and forty seven companies across all industries, including research labs set up by multi-national companies which are recognized by DSIR in India. Within the pharma and biotech space, there are less than two hundred. Mayuka Labs is now a part of this select group.

The Government recognition of its R&D center, apart from recognizing the innovative work being done by Mayuka scientists enables the company to enjoy a weighted tax deduction of 150% on its R&D expenses, along with complete exemption of duties on import of materials, equipment and machinery for R&D purposes.

About Mayuka Labs

New Delhi based Mayuka Labs was established in July, 2007 and set up its Research Labs in October 2007. The company is funded by US investors and offers Custom Research, Custom Synthesis and Custom Manufacturing services to innovator and generic companies across the world. Its R&D and pilot plant is in Nacharam Hyderabad and its API facility is located in Kopargaon, Maharashtra.

    Contact :

    Dr.Chandra Sekhar N K
    Chairman and Managing Director,
    Mayuka Labs Private Limited
    chandra@mayukalabs.com
    +91(0)11-46523601



'/>"/>
SOURCE Mayuka Labs Private Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
2. New nanotechnology centre helps turn big ideas into real products
3. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
4. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
5. New funding to charge energy research at UCL and the London Centre for Nanotechnology
6. European Centre for Modern Drug Discovery Established in Hamburg
7. Childrens Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey
8. Consistency, Flexibility Key in Improving Rewards & Recognition Programs
9. New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems
10. Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing
11. Synthetech Earns National Recognition for Performance Improvement Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):